Access. Assistance. Along the Journey.
Exelixis Access Services® (EASE) provides a variety of support to help your patients get started on treatment as soon as possible. EASE can meet the unique needs of your patients and practice at each step along the access journey.
YOUR EASE CASE MANAGER
- Can provide the status of your patient's access journey
- Offers prompt support with payer coverage, financial assistance, and treatment coordination
- Provides proactive follow-up
CONTACT EASE FOR MORE INFORMATION AND TO ENROLL
Monday to Friday, 8:00 AM to 8:00 PM ET
EASE Enrollment Form, including the 15-Day Free Trial Program, EASE Quick Start Program, EASE Co-Pay Program, and the EASE Patient Assistance Program (PAP)Download the form
15-Day Free Trial Program provides free drug to help patients start treatment quicklyDownload the form
HELP PATIENTS START AND STAY ON CABOMETYX® (cabozantinib)
Provides free drug to help patients start treatment quickly*†
Provides free drug to eligible patients who experience a payer decision delay of 5 days or more.*†
Eligible commercially insured patients pay $0 per month, for a maximum benefit of $25,000 per year.†
Provides a free 15-tablet supply in the lower dose to help patients who require a dose reduction.†
Eligible patients who cannot afford their drug costs may receive CABOMETYX free of charge.†
SUPPORT FOR COVERAGE DETERMINATION
At your request, EASE can provide support with:
- Benefits investigation
- Prior authorization (PA) assistance
- Appeals support and follow-up
*Limited to on-label indications. Additional restrictions and eligibility rules apply.
†Additional restrictions and eligibility rules apply.
This description of the Exelixis Access Services® (EASE) program is for informational purposes only. Exelixis* makes no representation or guarantee concerning reimbursement or coverage for any service or item. Information provided through the Exelixis Access Services program does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed healthcare provider, legal counsel, or applicable third-party payer(s). Exelixis reserves the right to modify the program at any time without notice.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) support the use of cabozantinib (CABOMETYX) in the treatment of both aRCC and HCC
National Comprehensive Cancer Network® (NCCN®)
As defined by the NCCN Guidelines®, preferred interventions are based on superior efficacy, safety, and evidence; and when appropriate, affordability.
*Data reflect use after sorafenib.
Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
aRCC=advanced renal cell carcinoma; HCC=hepatocellular carcinoma; TKI=tyrosine kinase inhibitor.